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WHY MANDATORY HIV TESTING OF PREGNANT
WOMEN AND NEWBORNS MUST FAIL: A
LEGAL, HISTORICAL, AND PUBLIC
POLICY ANALYSIS*
ELIZABETH B. CooPER**
INTRODUCTION
The debate surrounding mandatory HIV testing of newborns
and pregnant women requires an understanding of the historical
context of women in the epidemic. Although the epidemic first
was recognized in gay men in 1981,1 anecdotal reports reveal that
women already were dying from what seems to have been HIV-re-
lated symptomatology. Indeed, in Gena Corea's book, The Invisible
Epidemic,2 we learn that, as early as 1981, not insignificant numbers
of drug-using and former drug-using women were falling ill and
not recovering from conditions that normally are not fatal, includ-
ing bacterial pneumonia.3 Yet, because we did not necessarily ex-
pect these populations to be healthy4 or perhaps because our
health care system is not structured to recognize such changes,5 or
perhaps because, as Corea suggests, they were happening to
* A version of this paper originally was published as Historical and Analytical Overview of
Policy Issues Affecting Women Living with AIDS: A Blueprint forLearningfrom OurPast, 72 BULL.
OF N.Y. ACAD. MED. 283 (Summer Supp. 1995).
** Elizabeth B. Cooper is Associate Professor, Fordham University School of Law. The
author thanks Kristen Bebelaar, Tracie Gardner, Elyssa Gordon, Michael Kim, Minna
Kotkin, Nina Lowenstein, and Nancy Wackstein. Without their work and support, this arti-
cle would not be possible. All errors, however, are solely the responsibility of the author.
I CENTERS FOR DISEASE CONTROL, U.S. DEP'T OF HEALTH & HUM. SERV., Pneumocystitis
Pneumonia - Los Angeles, 30 MORBIDITY & MORTALIY WKLY. REP. 250, 250-52 (1981).
2 GENA CoREA, THE INVISIBLE EPIDEMIC (1993).
S Bacterial pneumonia was incorporated into the CDC's revised surveillance definition
of AIDS announced December 18, 1992. See id. at 1-3, 6, 12-15; CENTERS FOR DISEASE CON-
TROL, U.S. DEP'T OF HEALTH AND Hum. SERV., Immunodeficiency Among Female Partners of
Males With Acquired Immune Deficiency Syndrome (AIDS), 31 MORBIDITY & MORTALITY WKLY.
REP. 697, 697-98 (1983) [hereinafter CDC, Immunodeficiency].4 It appears that the stark contrast of severe morbidity and extraordinary mortality
among gay, mostly white, men, who otherwise would have been healthy, stood out in a way
that the increased morbidity and mortality among drug using women did not.
5 Some may be tempted to say that the increase in severity and occurrence of morbid-
ity and mortality went unnoticed because health care providers just did not care enough.
It would be far more appropriate, however, to take to task a health care system that neither
universally nor adequately provides health care services to those in need. Sheldon H.
Landesman & Susan Holman, Epidemiology and Natural History of HVInfetion, in PRIMARY
CARE OF WOMEN AND CHILDREN WITH HIV INFECFION 19, 27 (Patricia Kelly et al. eds., 1995);
R.P. Brettie & C.L. Leen, The Natural History of HIV and AIDS in Women, 5 AIDS 1283, 1283-
92 (1991).
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"others,"6 these deaths passed virtually unnoticed. We failed early
on to recognize that AIDS, as we later came to know the disease,
could and would manifest in women. Consequently, we lost critical
time in recognizing some of the symptoms that may accompany
HIV disease in women and in developing research and prevention
programs geared to the needs of women.
Remarkably, the first natural history study of HIV disease in
women was not commenced until 1992.1 Moreover, it was not until
1993 - after six years of research and advocacy, and ten years
since AIDS first was reported in women 8 - that the Centers for
Disease Control and Prevention ("CDC") recognized that HIV-re-
lated symptoms specific to women existed.9 Because the CDC did
not consider certain women-specific conditions to be HIV-related,
a number of things were happening: (a) the CDC was not getting
an accurate picture of the epidemic;' 0 (b) women were not being
properly diagnosed and, as a result, were getting H1V-related care
late in their illness, if at all, and were dying far more quickly than
other populations with HIV/AIDS;" (c) health care providers and
institutions did not integrate their gynecologic care into their HIV
6 CoP.A, supra note 2, at 4-5.
7 The CDC HERS (HIV Epidemiology Research Study) began in 1992. Communica-
tion with Sally Zierler, Dr. P. H., Associate Professor of Medical Science, Department of
Community Health, Brown University, Providence, R.I. (April 1995). See Landesman &
Holman, supra note 5.
8 In January 1993, the CDC had reports of 43 cases, since June 1981, of previously
healthy women who had developed opportunistic infections typical of AIDS. See CDC, Im-
munodefiiengy, supra, note 3.
9 Effective January 1, 1993, the CDC modified its surveillance definition of AIDS by
adding invasive cervical cancer to the list of AIDS-diagnosing conditions; the agency also
added recurrent pneumonia, pulmonary tuberculosis, and confirmed HIV-antibody tests
with T-cells (CD4+ cells) under 200 to the definition, and invasive cervical dysplasia to the
HIV classification system. CENTERS FOR DIsEAsE CONTROL, U.S. DEP'T OF HEALTH & HUMAN
SERV., 1993 Revised Classification System for HLIVInfection and Expanded Surveillance Case Defini-
tion for ALDS Among Adolescents and Adults, 41 MORBIDrnY & MoRTALIm WKLY. REP. 1, 1-10
(1992). Accuracy of the surveillance definition, in terms of specificity and sensitivity, is
important for maintaining accurate surveillance records. Surveillance is used to predict
trends in the epidemic, and implicitly, to direct funds as needed. Also, clinical trials largely
are established to examine those conditions recognized by the CDC as being one of the
now-33 AIDS-diagnosing events, and secondarily, by the host of non-AIDS-diagnosing but
iHlV-related conditions. See Risa Denenberg, Unique Aspects of HIV Infection in Women, in
WOMEN, AIDS AND ACTIVIsM 32 (The ACT UP/New York Women and AIDS Book Group,
1990); Landesman & Holman, supra note 5, at 19, 29-30. Therefore, a diagnosis of AIDS
can effect one's ability to access clinical drug trials.
10 Following implementation of the revised definition, there was a 182% rise in the
number of women diagnosed with AIDS and a 142% rise in diagnoses among men. Landes-
man & Holman, supra note 5, at 29-30.
11 Early studies of survival after AIDS diagnosis showed a shorter survival rate among
women than among men, related to poor access to care and later presentation with more
advanced symptoms. Although current studies of CD4 decline-per-year of HIV infection
among men show a fairly predictable rate, few comparable studies have been conducted on
women. Landesman & Holman, supra note 5, at 26. See also Brettle & Leen, supra note 5;
Denenberg, supra note 9, at 32.
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clinics and did not integrate HIV-related care into their gyneco-
logic care provision and, as a result, women got "underinclusive"
health care, and further, the CDC got an even more skewed look at
the epidemic;' 2 (d) the development of and access to clinical trials
did not reflect the medical needs of women in the epidemic, be-
cause trial development implicitly depended on the CDC's sanc-
tioning of certain conditions as being HIV-related or AIDS-
diagnosing;13 and (e) in our world of limited resources, access to
many services and benefits were highly dependent on receiving an
AIDS diagnosis; because it was largely women and low-income peo-
ple who had not yet been recognized in the surveillance definition,
these were the populations that also were disproportionately not
receiving benefits critical to their survival.' 4
Furthermore, by failing to recognize the depth and breadth of
the manifestation of HIV/AIDS in women, we also failed to under-
stand the degree to which the epidemic would become a family
disease. Even if only one person in a family unit were HIV-in-
fected, the impact would be felt throughout. This is particularly
true in single-parent households in which the mother is HIV-in-
fected; demographically, this is not an unusual occurrence.' 5
Moreover, as approximately twenty-five percent of the offspring of
HIV-infected women also will be HIV-infected,'6 concerns are
raised regarding school attendance, disclosure of serostatus, access
to appropriate caregivers in case of parental disability or death,
and a plethora of housing and government benefits issues.' 7
PART I - AN OVERVIEW OF THE POLICY IssuEs FACED BY WOMEN
LIVING WIT HIV/AIDS: FAILuRE OF THE ORIGINAL
AIDS MODEL OF HEALTH CARE DELIVERY
Although health care delivery systems are better established
now than in 1993 to provide gynecologic services for women with
12 Landesman & Holman, supra note 5, at 27; Denenberg, supra note 9, at 32-35.
13 Landesman & Holman, supra note 5; Denenberg, supra note 9; Carol Levine, Women
and HIV/AIDS Research: The Barriers to Equity, 13 IRB: A REV. OF HuMAN SUBJECTS RES. 18
(1991).
14 For a while, being AIDS-diagnosed was a prerequisite for receiving services from the
Division of AIDS Services (DAS) in New York City. See also S.P. v. Sullivan, No. 90 Civ. 6294
(S.D.N.Y. 1990) (Cedarbaum,J.) (analyzing a legal challenge to the Social Security Admin-
istration's failure to award benefits equitably).
15 Elizabeth B. Cooper, HI-Infected Parents and the Law: Issues of Custody, Visitation and
Guardianship, in AIDS AGENDA 69-117 (N.D. Hunter & W.B. Rubenstein eds., 1992).
16 NExv YORK STATE AIDS ADVISORY COUNCIL, REPORT OF THE SUBCOMMITTEE ON NEW-
BORN HIV SCREENING 6 (February 10, 1994) [hereinafter NEw YoRK STATE AIDS ADVISORY
COUNCIL]; Kenneth Mdntosh & Sandra K. Burchett, Clearance of HVesionsfiom Newborns,
332 NEv ENG. J. MED. 883 (1995).17 Cooper, supra note 15.
1996]
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HIV, the availability or provision of such services still is not uni-
form. At the 1995 HIV Infection in Women Conference,"8 one key-
note speaker, a woman living with HIV, stated that in her
numerous years of participating in a CDG-sponsored study, she had
not once been given a pelvic exam. Inversely, women still experi-
ence chronic yeast or other HIV-related gynecologic conditions
without being informed about the possible correlation with HIV,
let alone being provided with HIV-related education, counseling,
or the option of testing.
Second, women still have difficulty getting access to clinical
drug trials. The Food and Drug Administration ("FDA") has been
terribly lax in failing to eliminate extant barriers to HIV-positive
women's participation in phase I and early phase II clinical trials. 9
Even when formal barriers have been lifted, often implicit barriers
remain: there are instances in which women have been told they
must be sterilized or use Norplant in order to participate in trials.2"
Additional obstacles continue to exist. For example, there are few
clinical trials that are geared toward learning about HIV in women
as women, rather than as vectors of HIV to their offspring. 1 Also,
and not infrequently, referrals to clinical trials continue to occur
18 Address at the HIV Infection in Women Conference: Setting a New Agenda, Feb. 22-
24, 1995 [hereinafter HIV Infection in Women Conference]. The conference was coordi-
nated by the Philadelphia Sciences Group, and co-sponsored by the following government
agencies: National Institute of Health; Centers For Disease Control and Prevention; Food
and Drug Administration; Health Resources and Services Administration; Agency for
Health Care Policy and Research; Public Health Service Office on Women's Health.
19 In July 1993, the FDA issued new proposed guidelines permitting women living with
HIV, under certain circumstances, to participate in phase I and early phase II clinical trials.
There remains concern, however, that this change in policy, even when implemented, will
not be aggressively enforced. In January 1995, the National Task Force on AIDS Drug
Development recommended that the FDA change pertinent regulations to ensure that wo-
men are not excluded from clinical drug trials. The FDA indicated its willingness to make
such changes, but proposed regulations have not yet been put forward. Telephone Inter-
view with Theresa McGovern, Director of the HIV Law Project, in New York, N.Y. (Apr.,
1995) [hereinafter McGovern Interview].
20 The ACLU stood ready to challenge the failure of a NewJersey medical institution to
permit women to participate in phase I of a clinical drug trial. Specifically, a woman who
had had a hysterectomy sought to gain entrance to the trial. She was told that women were
not allowed to participate. By the time the ACLU learned of this incident, the clinical trial
had been discontinued because the drug was determined to be ineffective. Similar exclu-
sions have been reported anecdotally. Telephone Interview with Theresa McGovern, Di-
rector of the HIV Law Project, in New York, N.Y. (Summer, 1992); Interview with Marion
Banzhaf, Director of the New Jersey Women and AIDS Network, New Brunswick, N.J.
(Summer, 1992). It is expected that the most egregious exclusions will be minimized with
a change in FDA regulations. See McGovern Interview, supra note 20.
21 The first clinical trial that ostensibly focused on women, ACTG 076, actually was
designed to look at whether administration of AZT during pregnancy and labor and to the
child immediately after birth, could reduce maternal-child transmission rates. See Edward
M. Connor, M.D. et aL, Reduaion of Maternal-Infant Transmission of Human Immunodqficiency
Virus Type-I with Zidovudine Treatmen4 331 N-w ENG.J. MED. 1173 (1994). For further dis-
cussion of this clinical trial, see infra notes 33-38 and accompanying text.
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through an "old boys' network." This network generally is not
available to many women and adolescent girls living with HIV.
Demographically, women with HIV usually live on little money or
in poverty, and therefore depend on a public health care system
that is overburdened and not necessarily focused on broadening
access to clinical trials. 2 In addition, related to conditions of pov-
erty, women frequently need assistance with transportation, and
more importantly, child care, to participate in clinical trials.23
Third, women still have a very difficult time obtaining access
to drug treatment programs.2 4 Ghavkin 25 notes the nationwide
lack of drug treatment in general and in particular for women who
are pregnant or mothers of small children:
Out of the 24 states that have had criminal prosecutions of
women for drug use during pregnancy, only one of them have
[sic] any treatment available at all, and only two of them give
pregnant women priority access to drug treatment.
Frequently, such drug treatment programs are geared to heroin
addiction, rather than to crack, which has had particular impact on
women. In addition, programs rarely accept pregnant women, are
hesitant to accept women with HIV, and make no provisions for
child care - even though one's children can provide significant
motivation for breaking an addiction, and the fear of having one's
children placed in foster care can serve as a significant deterrent
from seeking drug treatment services.2 6
Fourth, we still have not developed sufficient support for wo-
men living with HIV for whom HW is a family-based concern. For
example, in many states, inadequate means exist for a woman to
arrange properly and comfortably for the care of her children for
the time if and when she becomes less able to care for them.27
22 Ironically, some physicians refer low-income patients to clinical trials as a means of
obtaining either improved health care or access to drugs that otherwise would not be fi-
nancially available. CJ. Rubin & M. Barry, Primary Care and Clinical Trials in H1VDisease:
Should Primary Care Providers Recruit for AiDS Trials, 6 AIDS CIiNICAL CARE 38, 38-40 (1994).
23 Denenberg, supra note 9, at 73; Kim Christensen, How Do Women Live?, in WOMEN,
AIDS AND AcrivisM 5, 7 (The ACT UP/New York Women and AIDS Book Group, 1990).
24 See Connor et al., supra note 21 at 1173.
25 Wendy Chavkin, Enemy of the Fetus: The Pregnant Drug User and the Pregnancy Police, 22
HEALTH/PAC Buu-. 5 (Winter, 1992).
26 Id. at 8-9.
27 Cooper, supra note 15; Lauren Shapiro, Legal Concrns of Women with H1VInfection, in
PRIMARY CARE OF WOMEN AND CHILDREN WI HIV INFECTION 259 (Patricia Kelly et al. eds.,
1995). Specifically, without statutory or regulatory authorization for the establishment of a
"standby guardianship," women frequently must choose between giving up custody before
they become ill or die without having settled matters, potentially leaving their children's
future care at-risk.
1996]
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Finally, to this laundry list, must be added issues of concerns of
violence. As reflected in the program and submitted abstracts at
the 1995 HIV Infection in Women Conference and elsewhere, 8
only now are we beginning to understand the impact of women's
fear of violence on their decision to be tested, to disclose their sta-
tus to their partners, or to insist on engaging in risk reduction with
their sex or drug-using partners.
Although a plethora of additional problems and obstacles face
women living with HIV/AIDS, I will turn here to the issue of
mandatory HIV testing of pregnant women and newborns.
PART II - MANDATORY TESTING OF PREGNANT WOMEN AND
NEwBORNs: A PARADIGM FOR THE DEVELOPMENT OF
DAMAGING PROGRAMS AND POLICIES
MEDICAL BACKGROUND
Increasing attention to maternal-infant HIV transmission, par-
ticularly in light of ACTG 076, a clinical trial indicating that adher-
ence to an AZT regimen may reduce such transmission,29 means
that there will be increasing calls for mandatory testing of
newborns, delivering women, and pregnant women. Indeed, legis-
lation has been introduced in New York, Illinois, Michigan, Penn-
sylvania, Florida, among other states, and the U.S. Congress, that
would result in the mandatory testing of newborns or pregnant wo-
men.30 One must assume that the purpose of mandatory testing of
pregnant women would be to "encourage" women to take AZT
during pregnancy as a means of reducing transmission rates and
that the purpose of mandatory testing of newborns would be to
encourage use of PCP prophylaxis and other treatments. As will be
addressed in greater detail infra, incidents involving coercive coun-
seling, testing, and treatment already have arisen and raise con-
cerns to be considered in the development of HIV counseling and
testing policy.
The discussion must begin with an examination of relevant
medical background. We know, for example, that the maternal-
28 Christensen, supra note 23; Richard L. North & Karen H. Rothenberg, Partner Notifi-
cation and the Threat of Domestic Violence Against Women with HIV Infection, 329 NEW ENG. J.
MED. 1194, 1194-96 (1993).
29 Connor et al., supra note 21. See also infra notes 33-36 and accompanying text.
30 As of this writing, no State has adopted mandatory HIV testing of pregnant women
or newborns. Rather, many States have begun to implement mandatory HIV counseling
programs, with the option to test, thereby benefiting pregnant and delivering women and
their newborns.
[Vol. 3:13
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infant HIV transmission rate is approximately twenty-five percent.3"
Preliminary data from clinical trial ACTG 076, announced in Feb-
ruary 1994, indicate the potential to reduce the vertical transmis-
sion rate by as much as sixty-seven percent.3 2  Preliminary
investigation indicated similar low levels of birth defects and mor-
tality in the newborns given AZT and those given a placebo. But, it
is not yet possible to know the long term effects of AZT on children
(e.g., with regard to growths, cancers, or other medical complica-
tions) or women (e.g., with regard to AZT resistance). 3
It is important to note that this trial began in the context of
significant community concern that adequate protections for wo-
men were not put in place and that the trial was not sufficiently
well-conceived to achieve its goals. For example, it was only after
preliminary reports from the trial were announced, and after much
community agitation, that researchers agreed to examine the long-
term impact of AZT use during pregnancy among women trial par-
ticipants; initially, follow-up studies were to focus solely on the
newborns.
In addition, it is noteworthy that the significantly reduced
transmission rates experienced in the trial are not expected to be
fully replicated when women are faced with tangible concerns not
present in the trial context, such as limited access to health care.
Further, because the trial involved women in good health, with
CD4 counts averaging above five hundred, it is not known whether
the protocol will be effective for women with more advanced HIV
31 N.vYORK STATE AIDS ADVISORY COUNCIL, supra note 16; McIntosh & Burchett, supra
note 16. Although virtually all newborns of HIV-infected women will test positive for HIV
antibodies for the first 12-18 months of life, this actually reflects the transmission of the
mother's HIV antibodies to the child. New testing technology can determine whether a
child actually is infected, or merely is carrying maternal antibodies, by the age of three to
six months. In fact, only 20-25% of children born to HIV-infected women (in the U.S.)
actually are infected with HIV.
32 Approximately 477 women were enrolled in ACTG 076. Women were divided into
two groups: those given AZT and those given a placebo. The drug/placebo was adminis-
tered orally during the second and/or third trimester of pregnancy and intravenously dur-
ing delivery; in addition, the newborn received the same substance as its mother for the
first six weeks of life. In the placebo group, the transmission rate was 25.5%; in the AZT
group, the transmission rate was 8.3%. Connor et al., supra note 21, at 1173.
33 Connor et al., supra note 21. ACTG 219, "Pediatric Late Outcomes Protocol," will
monitor pediatric participants' use of ACTG 076 "for the possible development of un-
known late effects of the study treatment" through age 20. Memorandum from Jack Moye,
Jr., MD, Pediatric, Adolescent and Maternal Branch, Center for Research for Mothers and
Children, National Institute of Child Health and Human Development, National Institutes
of Health, to the members of the Northern Manhattan Pediatric AIDS Demonstration Pro-
ject and the HIV Center for Clinical and Behavioral Studies 5 (Apr. 6, 1994). The memo
was prepared for a meeting on Ethical, Legal and Policy Implications of Recent Findings
on the Prospect of Reducing the Transmission of HIV from Pregnant Women to Their
Babies, sponsored by the HIV Center for Clinical and Behavioral Studies, Columbia Univ.
School of Pub. Health and AmFAR (the American Foundation for AIDS Research).
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illness.3 4 We also do not yet know the usefulness of the protocol
for women with previous use of AZT or for women with AZT-resis-
tant virus. Moreover, it is not known which part of the protocol,
which involved the intake of AZT at three different points - gesta-
tion, delivery, and after birth - was effective in helping to reduce
transmission a5 Finally, we must discover any effect on transmission
of vitamin A36 - a relatively accessible and affordable substance -
viral load, 7 and other factors, and provide that information to
HL-positive women considering pregnancy and delivery options.
THE SOCIO-POLITIcAL LANDSCAPE
Because the women primarily affected by HIV are likely to be
low-income women of color - women traditionally visited with un-
due coercion regarding reproductive choice and forced steriliza-
tion38 - the political landscape of how the "lessons" of ACTG 076
will be implemented must be subject to close scrutiny. For exam-
ple, although the Public Health Service recently has issued guide-
lines on the counseling of HIV-positive women on the use of AZT
in pregnancy,39 and now with regard to testing and counseling,40
34 Note, however, that women with lower CD4 cells may choose to take AZT because of
their own declining CD4 count.
35 Connor et al., supra note 21.
36 A study in Blantyre, Malawi, in south central Africa, conducted by Richard Semba,
MDJohns Hopkins School of Medicine, and researchers from Malawi, suggest that vitamin
A deficiency is associated with an increase of three to four times the risk of mother-to-child
transmission of HIV and a higher infant mortality rate [hereinafter Semba study]. In the
study, 93.3% of infants born to the mothers most deficient in vitamin A died in the first
year of life. Only 14.2% of the children born to the mothers with the healthiest vitamin A
levels died within a year. Vitamin A stores are depleted during birth and pregnancy, and a
shortage of Vitamin A weakens an already compromised immune system. See Deficiency
Linked with Increased HIV Transmission/Mortality, AIDS WEEKLY, Feb. 20, 1995, at 13; Tan
Sheet, 3 F.D.C. REPORTS 38 (1995); Blue Sheet, 37 F.D.C. REPORTS 11, at 11-12 (1994). In
a press briefing, Dr. Semba stated that, "This study raises the possibility that giving daily
vitamin supplements to HIV-infected women during pregnancy may reduce the transmis-
sion of HIV from mother to child and may reduce mortality of both mother and infant....
It is now an urgent issue and unanswered question whether something as simple as vitamin
A, which costs two cents per capsule, may be an appropriate therapy during HIV infection."
See Blue Sheet, 38 F.D.C. REPORTS 14, 14-15 (1995).
37 Blue Sheet, 38 F.D.C. REPORTS 14-15; B. Weisner et al., Quantification Human Immu-
nodefiiency Virus Type 1 During Pregnancy: Relationship of iral Titer to Mother-to-Child Trans-
mission and Stability of Viral Load, 92 PROC. NAT'L AcAD. Scr. 8037, 8037-41 (1994); Blue
Sheet, 37 F.D.C. REPORTS 9, 9-10 (1995).
38 Helen Rodriguez-Trias, Presidential Address at the 121st annual meeting, American
Public Health Association (Oct. 25, 1993). See also Dorothy E. Roberts, The Future of Repro-
ductive Choice for Poor Women and Women of Color, 14 WOMEN'S RTS. L. REP. 305 (Spring-Fall,
1992).
39 CENTERS FOR DISEASE CONTROL., U.S. DEP'T OF HEALTH & HUM. SERV., Recommenda-
tions for the Use of Zidovudine to Reduce Perinatal Transmissions of Human Immunodeficiency
Virus, 43 MORBIDrIY & MORTALrrY WKLY. REP. 1, 1-20 (1994).
40 Draft U.S. Public Health Service recommendations for H1V Counseling and Testing
of Pregnant Women, 60 FED. REG. 10086 (Feb. 23, 1995).
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there remains concern that health care workers may attempt to co-
erce women into taking AZT, disregarding a perhaps well-consid-
ered decision whether to take the drug." Inversely, there is
concern that women who wish to have access to the 076 AZT regi-
men during pregnancy will have limited access to treatment, much
as they already may have limited access to care.4 2
Although some are placing great emphasis on the importance
of the increasing numbers of women who know their serostatus,
and although it is important that women have the option of learn-
ing their serostatus, the manner in which this option is presented is
even more important. First, many more women may already know
their status than are perceived by health care providers; they may
choose not to self-disclose because they fear discrimination, stigma,
or breaches of confidentiality. Second, women, like men, may
choose not to know their serostatus because of the many extant
barriers to testing, including ongoing fears of breaches of confi-
dentiality, insufficient access to care and services for those who test
positive, and continuing discrimination against people (and fami-
lies) with HIV.43
As we have seen throughout the epidemic, mandatory testing
programs frighten people away from services. For example, dur-
ing the two years the state of Illinois required HIV-antibody testing
of people seeking marriage licenses," approximately forty-thou-
sand people left the state to get married elsewhere.4 When New
York City required newborns to be screened for drug metabolites
and started a policy of automatically initiating procedures to re-
move children testing positive from their mothers, there was a sig-
41 INSTITUTE FOR FAMILY-CENTERED CARE, Focus GROUP ON ACTG, PRELIMINARY REPORT
(1994). There already have been reports of health care practitioners attempting to involve
child welfare agencies when a mother has refused AZT for her newborn. Presentation of
Theresa McGovern to the Ad Hoc Committee on AIDS of the Assoc. of the Bar of the City
of New York. As will be discussed infra notes 54-73 and accompanying text, there is neither
medical nor legal support for such actions. See also Editorial, Zidovudine [AZT] for Mother,
Fetus, and Child: Hope or Poison , 334 THE LANcEr 207 (1994).42 Landesman & Holman, supra note 5, at 26.
43 In a 1990 report, the ACLU concluded that "HIV-related discrimination occurs all
over America, cutting across lines of race, gender, ethnicity and sexual orientation; it af-
fects a wide spectrum of people ranging from those with full-blown AIDS to those helping
to take care of them; and it is on the rise." ACLU AIDS PROJECT, EPIDEMIC OF FEAR: A
SURvEY OF AIDS DISCRIMINATION IN THE 1980s AND POLICY RECOMMENDATIONS FOR THE
1990s 1 (1990). The ACLU's nationwide survey also indicated that such discrimination
often is experienced in areas crucial to survival, including insurance, housing, and access
to care and government benefits.
44 Ill. Rev. Stat. § 5-204, as amended by Ill. Pub. Act 86-884 (Sept. 11, 1989).
45 Isabel Wilkerson, Pre-Nuptial AiDS Screening Taxes Illinois Health System, N.Y. Times,
Jan. 26, 1988, at Al; E. Taylor, Illinois Law Offers a Futile Exercise in Combating AIDS, Chi.
Trib., Sept. 8, 1989, at C27; Enstad, AIDS Test Has 40, 000 Fleeing State to Wed, Chi. Trib.,Jan.
4, 1989, at C1.
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nificant increase in the number of babies not taken home from the
hospital; women feared prosecution or assumed that their children
would be taken from them regardless.46 Finally, it is worth noting
that disproportionately high testing rates occur at anonymous HIV-
antibody sites located across the border from states that require
testing sites to report the names of all people testing HIV-
positive.47
By strong contrast, when HIV-related counseling is offered
universally in pre-natal and delivery settings, and testing is volun-
tary, confidential, and linked to available care and services, preg-
nant and parturient women overwhelmingly consent to testing.
For example, at Harlem Hospital in New York City, more than
ninety percent of counseled women consent to testing;4 8 similar
proportions are found in Cook County Hospital in Chicago,49
Johns Hopkins in Baltimore,50 Grady Hospital in Atlanta,5' and at
numerous other sites.52 Notably, the patient population at each of
these hospitals is overwhelmingly poor and African-American, wo-
men who stereotypically - and falsely - are perceived as being"non-compliant" or "difficult" patients. Yet, consent-to-testing rates
and rates of bringing HIV-positive children and their mothers into
care are consistently high. In other words, these programs work.
LEGAL ANALYSIS
Finally, it is important to assess the legal prospects of a
mandatory testing program. Many legal experts believe that such
46 Vicki Breitbart et al., The Accessibility of Drug Treatment for Pregnant Women: A Survey of
Programs in Five Cities, 84 AM.J. PUB. HEALTH 1658, 1658 (1994).
47 AIDS ACTION FOUNDATION, SHOULD HIV TEST REPORTS BE REPORTABLE?: A Discus-
SION OF KEY POuCY QUESTIONS (1993).
48 NEW YORK STATE AIDS ADVISORY COUNCIL, supra note 16.
49 Interview with Mardge Cohen, MD, Director, Women and Children's HIV Program,
Cook County Hospital, in Chicago, Ill. (July 1994) [hereinafter Cohen Interview].50 According to Dr. Jean Anderson atJohns Hopkins Hospital, Baltimore, "if it's [test-
ing] presented in a reasonable way, people are going to accept screening; to force them
into it is only going to drive them away and alienate them." More than 90% of women who
receive obstetric care at the clinic atJohns Hopkins voluntarily agree to be tested. Chris-
tine Gorman, Mons, Kids, and AIDS, TIME, at 60 (July 4, 1994).
51 Michael K. Lindsay et al., Determinants of Acceptance of Routine Voluntary Human Immu-
nodeficiency Virus Testing in an Inner-city Prenatal Population, 78 OBSrTE. & GYNECOL. 678, 678
(1991) [hereinafter Lindsay, Determinants]; Michael K. Lindsay et. al., Routine Antepartum
Human Immunodeficiency Virus Infection Screening in an Inner-city Population, 74 OI3s-r.
GYNECOL. 289, 289 (1989) [hereinafter Lindsay, Screening]; CENTERS FOR DISEASE CONTROL
AND PREVENTION, QUESTIONS AND ANSWERS: CDC DRAFT GUIDELINES FOR HI COUNSELING
AND VOLUNTARY TESTING FOR PREGNANT WOMEN 2 (1995) [hereinafter CENTERS FOR DISEASE
CONTROL, QUESTIONS AND ANSWERS].
52 At the HIV Infection in Women Conference, Dr. Judith Cohen and Dr. Carmen
Zorilla each identified a number of sites, particularly in California and in Puerto Rico, at
which similarly high consent-to-testing rates were observed. See HIV Infection in Women
Conference, supra note 18.
[Vol. 3:13
HeinOnline  -- 3 Cardozo Women's L.J. 22 1996
MANDATORY HIV TESTING
programs likely would be found to violate many of a woman's con-
stitutional and statutory rights. These rights include:
The Right to Privacy. A woman's right to privacy includes the
right to bodily integrity,53 including the right to make personal de-
cisions regarding medical tests and treatment.' The state cannot
intrude on a person's right to privacy in the absence of a compel-
ling state interest; moreover, any intrusion must be "narrowly tai-
lored" to meet that interest.5 The right to privacy also includes
one's interest in avoiding disclosure of personal matters, including
HIV status.56 A number of states, including New York, have en-
acted statutes creating a level of HIV-related confidentiality that
surpasses general medical confidentiality.5" The protections re-
garding bodily integrity and personal decision-making are most
philosophically appropriate and availing.
The Right to Informed Consent. Although this right specifically is
found in many state HIV-specific statutes regarding consent to test-
ing and confidentiality, its underpinnings can be found in the
broader constitutional principles of privacy and due process which
provide that individuals are imbued with a right to bodily integ-
rity.5 8 The right to informed consent includes the right to refuse
or forego medical treatment59 and remains intact even if the intru-
sion is for the benefit of another, including a fetus. 0 Moreover,
the state may not promote an identified interest in potential life by
providing misleading information; rather, the "validity of a state's
informed consent requirement rests on its interest in ensuring that
the mother's consent is fully informed."6 '
53 Cruzan v. Director of Missouri Dept. Health, 497 U.S. 261 (1990).
54 Id.; Roe v. Wade, 410 U.S. 113 (1973); Thornburgh v. Am. College of Obstetricians
and Gynecologists, 476 U.S. 747, 770 (1986) (holding that a woman cannot be forced to
undergo any procedures that increase the risk to her life and health for the sake of her
fetus).
55 Nixon v. Adm'r of Gen. Serv., 433 U.S. 425 (1977); Carey v. Population Serv. Int'l.,
431 U.S. 678, 686 (1977).
56 Whalen v. Roe, 429 U.S. 589, 599-600 (1977); Doe v. The City of New York, 15 F.3d
264 (2d Cir. 1994); Doe v. Barrington, 729 F. Supp. 276, 384 (D.N.J. 1990); Nixon v. Adm'r
of Gen. Serv., 433 U.S. 425, 457 (1977); Nolley v. County of Erie, 776 F. Supp. 715, 728
(W.D.N.Y. 1991).
57 N.Y. PUB. H-ALTH LAW §§ 2780(7), 2782.
58 Cruzan, 497 U.S. 261; see also Ohio v. Akron Center for Reproductive Health, 497 U.S.
502 (1990); Canterbury v. Spence, 464 F.2d 772, 788 (D.C. Cir.), cert. denied, 409 U.S. 1064
(1972); In reA.C., 573 A.2d 1235, 1243 (D.C. 1990).
59 Bee v. Greaves, 744 F.2d 1387, 1392-1393 (10th Cir. 1984), cert. denied, 469 U.S. 1214
(1985).
60 See In reA.C., 573 A.2d at 1235 (emphasizing that fetus does not have rights superior
to the mother); Bonner v. Moran, 126 F.2d 121, 122 (D.C. Cir. 1941) (requiring consent
for "a surgical operation not for the benefit of [that] person but for another"). See also
Thornburgh v. Am. College of Obstetricians and Gynecologists, 476 U.S. 747 (1986).
61 Correspondence from the Center for Reproductive Law and Policy to Members of
the NewYork State Legislature, May 16, 1994 (citing Akron v. Akron Center for Reproduc-
1996]
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At least one court has acknowledged that testing for HIV with-
out informed consent "would actually have a negative impact on
the epidemic because those individuals will be deterred from seek-
ing medical treatment .... [I] t will create an atmosphere of dis-
trust in the physician and patient relationship....2 For each of
these reasons, the exclusion of pregnant or parturient women as a
class from the parameters of informed consent protocols, or, a re-
duction in the protections afforded by such protocols, would be
difficult to defend.63
The Right to Make Medical Decisions on Behalf of One's Children.
This right, also essentially part of one's rights to privacy and due
process, lies in parents' interest in raising their children without
undue state interference.64 The implicit presumption that parents
will act in the best interest of their children generally is upheld,
unless there is some indication that a parent is refusing life-saving
or curative treatment to the child - a concept not so applicable
with regard to a fetus. 65 Although prophylaxis is available that may
help prevent PCP in infants, it is neither uniformly effective nor
universally implemented. 66 As important, the state first would have
tive Health, 462 U.S. 416, 448 (1982); Planned Parenthood v. Casey, 112 S. Ct. 2791, 2823
(1982). See also Maher v. Roe, 432 U.S. 464, 473 (1977), Crain v. Allison, 443 A.2d 558, 562
(D.C. 1982).62 Hill v. Evans, No. CIV.91-A-626-N, 1993 U.S. Dist. LEXIS 19878, at *23 (M.D. Ala.
1993).63 Attempts to mandate testing of pregnant or delivering women or their newborns -
or to reduce counseling and consent requirements prior to testing - under the guise ofan emergency exception to the informed consent doctrine similarly is unavailing. See, e.g.,N.Y. St. Reg., I.D. No. HLT-50-95-00009-P (to be codified at N.Y. Comp. Codes R. & Regs.
tit. 10) (proposed Dec. 13, 1995). First, virtually any HIV-related health emergency can be
treated without an HIV diagnosis. The presenting symptom is attended to, and, if appro-priate, a presumption of HIV infection is made. Counseling to encourage HIV testing is
continued. Still, care cannot be denied on the basis of an individual's refusing to betested. Second, newborns tend not to be at risk for opportunistic infections, specifically
PCP pneumonia, until age 3-6 months; the CDC recommends that PCP prophylaxis not
commence until age one month. Therefore, a substantial window exists for continued
HV-related counseling of the mother following the birth of the child. Third, should aparent not be competent to consent or refuse to consent to testing, the care provider has a
number of options. For example, if the child has been removed to foster care, the consent
process is likely to change significantly, facilitating access to testing should the state find itnecessary. In another example, if a parent acts in a manner perceived by careproviders to
be not in the child's best interest, the provider can take advantage of existing legal mecha-nisms to ensure that the child receives appropriate care. For each of these reasons, partic-
ularly considered in light of the overwhelming consent-to-testing rates found when careand confidentiality are assured, it is nigh impossible to construe an appropriate "emer-
gency" exception to existing consent requirements prior to administering an HIV-related
test.
64 Meyer v. Nebraska, 262 U.S. 390 (1923); Santosky v. Kramer, 455 U.S. 745 (1982). See
also Hodgson etal. v. Minnesota, 497 U.S. 417, 480 (1990); Matter of Hofbauer, 393 N.E.2d
1009, 1013 (N.Y. 1979).
65 Matter of Hofbauer, 393 N.E.2d 1009, 1013 (N.Y. 1979).
66 For example, infant medical records in New York City revealed that of 29 seroposi-
tive infants born who were later diagnosed with PCP, only seven had received prophylaxis.
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the obligation to seek the consent of the mother, through counsel-
ing, with regard to both testing and treating the child. As has been
shown, women consistently consent to testing in this context.
The Right to Equal Protection. As a rule, the government cannot
adopt policies that treat women, as a class, differently from the
manner in which it treats all others, unless it can establish that this
differential classification serves an important governmental objec-
tive and that the discriminatory policy is substantially related to the
state's articulated goal.6" The prohibition on treating members of
racial minorities in a discriminatory manner is even more exacting.
Although these are theoretically appealing and sound claims, in
practice, they are least likely to be availing in a court of law.68
Based on the foregoing, mandatory testing HIV programs may
well be found to violate many of a woman's constitutional and stat-
utory rights. 69 Similarly, it would be highly unethical - and illegal
- to force a woman to take AZT without her full voluntary and
informed consent.70 First, all women must be counseled with re-
gard to the possible risks and benefits (to herself and her child) of
this potentially toxic treatment. Attendant to the obligation to pro-
vide counseling is the understanding that the patient has the right
to refuse even recommended treatment. This right is not eviscer-
Also, PCP occurs in approximately 30% of newborns receiving prophylaxis. NEmv YORK
STATE AIDS ADvISORY COUNCIL, supra note 16, at 16-17. See also B.W. Levin, J.M. Discoll,
A.R. Fleischman, Treatment Choice for Infants in the Neonatal Intensive Care Unit at Risk for
AIDS, 265J. AM. MED. Assoc. 2976 (1991) (survey of care providers revealed that perceived
HIV status may negatively affect provider decision-making about treatment for non-HIV-
related conditions for critically ill infants, including those not actually infected).67 Reed v. Reed, 404 U.S. 71 (1971); see Schlesinger v. Ballard, 419 U.S. 498, 506-07
(1975) (requiring heightened scrutiny because danger that government policies may be
reflective of "archaic and overbroad" generalizations about gender).68 Washington v. Davis, 426 U.S. 229, 238 (1976); Loving v. Virginia, 388 U.S. 1, 11
(1967); Wygant v. Jackson, 476 U.S. 267 (1986); see also Richard v. Croson Co., 488 U.S.
469, 493 (1989) (noting the difficulty of distinguishing "benign" or "remedial" classifica-
tions from those motivated by discrimination of race).69 The currently-proposed regulation in New York State, see supra note 63, designed to
reduce counseling and lessen or eliminate consent procedures for delivering women, is
also subject to significant legal challenge. Indeed, principles of bodily integrity and in-
formed consent are put at-risk in the proposal. The New York statute regarding HIV test-
ing, see supra note 57, would be effectively vitiated for pregnant and delivering women. As
explained supra note 63, the exceptions for testing in an "emergency" are inconsistent with
both medical knowledge concerning HIV and existing legal standards. Moreover, to the
extent such "emergency" testing is predicated on perceptions of risk, the state is likely to
encounter an equal protection challenge. See Hill v. Evans, No. CIV.91-A-626-N, 1993 U.S.
Dist. LEXIS 19878, at *27 (M.D. Ala. Oct. 7, 1993). Finally, based on the actual mechanism
for testing and processing test results, the proposal runs afoul of state and federal statutory
protections found in the respective human subjects laws.
70 See Washington v. Harper, 494 U.S. 210, 229 (1990) ("The forcible injection of medi-
cation into a nonconsenting person's body represents a substantial interference with that
person's liberty").
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ated for pregnant women. In fact, absent extraordinary circum-
stances - not present in this context - a woman legally cannot be
forced to accept medical intervention she does not wish to have.7 1
It would be inappropriate to yield to the expectation of some that
every HIV-infected pregnant woman should take AZT regardless of
her own risk assessment for taking this potent drug.7 2
PERSPECTIVES OF WOMEN LiNG WITH HIV
Regardless of the construct of the analysis of mandatory test-
ing programs, one always must return to the reality of life for the
HIV-infected woman. One cannot ignore the anecdotal reports of
numerous HIV-positive women that implementation of a
mandatory testing program would result in more women avoiding
pre-natal care and avoiding hospital deliveries;7 this likely would
be particularly true for immigrant and undocumented women, for
whom a positive HIV-antibody test may provide grounds for depor-
tation, as it is grounds for barring non-citizen aliens entry to the
United States.74 We also cannot ignore that implementation of a
mandatory testing program would make the receipt of health care
contingent on an individual's being tested for HIV, a principle uni-
formly rejected until now. Indeed, it seems odd to establish a bar-
rier requiring a pregnant woman to be tested as a pre-requisite for
getting health care, including pre-natal care.
Through a mandatory testing program, the state would insert
itself between the mother and her child with the message that the
state is a better caretaker than the mother. This mode of state in-
tervention.sets the stage for broader intrusions of the government
into the lives of women and their children. Concern over such in-
trusions, particularly the removal of children to foster care, histori-
cally has worked to discourage women from seeking services that
might otherwise be beneficial to them or their families.75 Also out-
standing is the concern that a state might prosecute HIV-infected
women for transmitting HIV, in much the same way that women
have been charged with violating drug statutes when their children
71 In reA.C., 573 A.2d 1285, 1246 (D.C. Cir. 1990).
72 INSrrrUTE FOR FAMILY-CENTERED CARE, supra note 41.
73 Id. Participants in HIV-related education and advocacy efforts coordinated by the
New York Task Force on Women and AIDS. See also, Hill v. Evans, No. CIV.91-A-626-N,
1993 U.S. Dist. LEXIS 19878, at *23 (M.D. Ala. Oct. 7, 1993).
74 8 U.S.C. § 1182(a) (1994).
75 Breitbart et al., supra note 46.
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are born with drug metabolites; 76 indeed, such HIV-related prose-
cution already is at least technically possible in four U.S. states.77
A POLICY PROPOSAL
Based on the foregoing analysis, or elements thereof, many
experts have concluded that access to care for women and their
children is best facilitated through universal HIV-related education
and counseling, with an offer of testing.7" Moreover, although it is
useful for a woman to learn her serostatus after delivery, learning it
before she becomes pregnant or during pregnancy will give her a
wider range of prevention, treatment, and reproductive options.
And, although early identification is important, alone it is not
enough; counseling and testing must be linked to care, services,
and confidentiality to have value.79 Moreover, as we encourage
routine counseling with the offer of testing, this must not be inter-
preted as an implicit invitation to mandatory testing. Finally, we
must ensure that the quality of care a woman receives is not linked
to her decision to be tested or not tested.
This is not a matter of babies' rights versus women's rights: we
cannot forget that perhaps the most important factor in a baby's
health care is the mother.8 0 By building policy on the borne-out
societal assumption that a pregnant woman, including an HIV-posi-
tive pregnant women, is interested in giving birth to a healthy baby,
we foster, rather than undermine, the critical provider-patient trust
relationship.8 ' This more comprehensive approach both respects
76 Telephone Interview with Nina Lowenstein, Aaron Diamond Fellow, Center for Re-
productive Law and Policy (Apr. 1995).
77 Michael Closen et al., Criminalization of an Epidemic: HV/AIDS and Criminal Exposure
Laws, 46 ARizt L. REv. 921 (1994).
78 This approach has been endorsed by the American Medical Association, American
Nurses Association, American Academy of Pediatrics, American College of Obstetricians
and Gynecologists, American Public Health Association, and the Institute of Medicine,
among others. See also preceding discussion concerning the success of universal counsel-
ing and voluntary programs.
79 Having a testing program in place does not ensure the availability of a treatment and
care program. Wendy Chavkin, MD, MPH, Testimony to the New York State Advisory
Council Subcommittee on Newborn Screening (Nov. 8, 1993). See also NEW YORK STATE
AIDS ADvISORY COUNCIL, supra note 16, at 16-17 ("Among infants in New York City identi-
fied as HIV-positive prior to diagnosis ... 22 of 29 had not received prophylaxis").
80 Indeed, when care for newborns replaces care for both mother and child, a woman's
role narrows falsely to that of carrier and deliverer of newborn.
81 If it is determined that a parent is acting in a manner that would constitute abuse or
neglect, mechanisms currently exist in the law for health care providers, child welfare
agencies, or other appropriate parties to pursue means of improving the welfare of the
child, including, if necessary, the removal of the child from the home.
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individual autonomy and protects the public health - benefiting
both mother and child. 2
It is disturbing that proposals to mandatorily test newborns
and pregnant women are being considered seriously by many state
legislatures. In fact, it is alarming when any arm of the government
(legislative, executive, orjudicial) chooses to pursue a path of pol-
icy development that not only has not been endorsed by, but in
fact has been rejected outright, by virtually every well-respected
medical, scientific, and public health organization. 3
Most policy makers seeking to implement mandatory testing
programs assert that there is a countervailing and compelling rea-
son to ignore this virtual medical consensus: the welfare of the
children. Yet, implicit in the argument that we must mandate test-
ing to preserve the health and well-being of our children is the
belief that mothers will not act to best preserve the welfare of their
children. In most circumstances, this notion would have family-
rights advocates and many others up in arms. Therefore, we must
question why the response of some policy-makers to the develop-
ment of critical medical interventions is to seek to eliminate or de-
crease the HIV-related counseling and consent, essentially
reducing the degree of information and autonomy afforded preg-
nant and delivering women. We also must question the apparent
ease with which policy-makers are willing to establish a different
degree of H1V-related consent from pregnant and delivering wo-
men than is required from all other people.
Perhaps boldly, I suggest that this aberration may well adhere
to the demographics of the epidemic. Advocates for mandatory
testing frequently appear to yield to an assumption that HIV-in-
fected women - the vast majority of whom are poor or have low
incomes, are women of color, and some of whom have a history of
drug use - do not adhere to an otherwise intact societal assump-
tion that women will act in their children's best interest. Ironically,
as noted above, when women are provided with information -
when they are told of the advantages and the disadvantages of be-
ing tested including non-biased information about possible inter-
vention and treatment, and when care and services are available to
them - women overwhelmingly consent to testing. And, it is in
82 NEW YORK STATE AIDS ADVISORY COUNCIL, supra note 16; Gorman, supra note 50;
Lindsay, Determinants, supra note 51; Lindsay, Screening, supra note 51; CENTERS FOR DIS-
EASE CONTROL, QUESTIONS AND ANSWERS, supra note 51; THE ASSOCIATION OF THE BAR OF
THE CITY OF NEW YORK, PRENATAL/NEWBORN HIV TESTING (1994); Cohen Interview, supra
note 49; HIV Infection in Women Conference, supra note 18.
83 See supra note 66.
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this context that both they and their children are brought into crit-
ical and appropriate HIV-related health care.
Therefore, I fear false perceptions concerning race, class, HIV,
and the role of health care providers, underlie good-hearted, but
misguided policies concerning mandatory HNV testing of pregnant
women and newborns. In almost every other context, as a society,
we support the provision of information to the patient and we sup-
port patient and familial decision-making autonomy. Yet, here,
proponents of mandatory testing seek to carve out an exception to
these well-founded presumptions - presumptions that have been
repeatedly validated in the context of HIV counseling, testing, and
care.84 There is no doubt that medical interventions are critically
important developments in our efforts to reduce the prevalence
and virulence of HV/AIDS. However, as a society, we must remain
vigilant that policies are developed in a manner that facilitates ac-
cess to these interventions, if they are desired.
PART III - CONCLUSION AND STEPS FOR THE FUTURE
The construction of valid, useful, respectful policies concern-
ing women living with HIV/AIDS necessarily requires that our pol-
icy-makers, be they legislators, judges, government administrators,
or hospital administrators, listen more attentively to the voices of
these women. Indeed, a review of our history and an analysis of
our present circumstances compel but one conclusion: despite the
soaring numbers of women infected with HV,8 5 policy frequently
is developed without the input of those who will be most affected
by its development. The invisibility of women living with HIV must
be corrected if we are to have hope for the development of sound
AIDS policy. Consider the following: had women been recognized
earlier on in the epidemic, we would have had the opportunity to
develop more-effective prevention and treatment mechanisms; we
would have had a chance to develop more-appropriate clinical tri-
als; we would have given more people a chance to rightfully obtain
84 NEW YORK STATE AIDS ADVISORY COUNCIL, supra note 16; Gorman, supra note 50;
Lindsay, Determinants, supra note 51; Lindsay, Routine, supra note 51; CENTERS FOR DISEASE
COITROL, QUESTIONS AND ANswERS, supra note 51; Semba Study, supra note 36; HIV Infec-
tion in Women Conference, supra note 18.
85 The World Health Organization ("WHO"), focusing its attention on the worsening
impact of HIV disease on women, has predicted that by the end of the 1990s the number
of women infected with HIV will be double what it was at the beginning of the decade.
WHO estimates that AIDS will kill at least 2 million women this decade. U.S. DEP'T
HEATH & Hum. Sratv., AIDS Among Women to Double by 2000, 106 U.S. PUB. HEALTH REp.
216 (1991).
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government benefits that others could more easily obtain. Funda-
mentally, the epidemic would not have developed as it has.
Many of our policymakers are tired of the epidemic. They
want it to go away. So do we. But making the epidemic go away
does not mean shunning people who have HIV/AIDS. Instead, it
means bringing all of us closer together: listening, talking, build-
ing trust, and building policies and programs that will help, not
hurt, women living in the HIV/AIDS epidemic.
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